---
$id: https://graph.org.ai/products/commodity/51131719
$type: Product
source: UNSPSC
code: "51131719"
title: "Apafant"
class: "51131700"
classTitle: "Thrombolytic drugs and platelet aggregation inhibitors"
family: "51130000"
familyTitle: "Hematolic drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Apafant

**UNSPSC Code**: 51131719
**Class**: [Thrombolytic drugs and platelet aggregation inhibitors](Thrombolytic drugs and platelet aggregation inhibitors.mdx)
**Family**: [Hematolic drugs](../Hematolic drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an antiplatelet agent with the molecular formula C22H22ClN5O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J613NI05SV, chemically known as 4-(3-(4-(o-chlorophenyl)-9-methyl-6h-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepin-2-yl)propionyl)morpholine but generally known as apafant, which bears US NIH Compound Identifier 65889. European Medicines Agency schedules Apafant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05533MIG. The term APAFANT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). APAFANT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule apafant under HS 29349990 and SITC 51579. As of Q4 2014, APAFANT remains the US FDA Preferred Term for this commodity. Apafant bears US NLM identifiers UMLS ID C0245118 and NCI Concept Code C77989. SMILES: CLC1C(C2=NCC3N(C4SC(CCC(=O)N5CCOCC5)CC24)C(NN3)C)CCCC1.

